There are two types of castleman disease unicentric and multicentric. Unicentric castleman disease affects only a single area or group of lymph nodes while multicentric castleman disease can affect lymphoid tissues around the body. Castleman disease is not life threatening except for the HIV-associated multicentric castleman disease.
Government support for the development of orphan drugs and allowing premium pricing of these drugs will be helpful in generating high revenue for companies. High unmet need also expected to drive the growth of castleman disease treatment market.
On the basis of therapy
- Monoclonal Antibodies
- Chemotherapy
- Radiation Therapy
- Immunotherapy
- Corticosteroids
- Antiviral Drugs
On the basis of end users
- Hospitals
- Clinical
- Ambulatory Care Units
For the entire list of market players, request for Table of Content here @ https://www.persistencemarketresearch.com/toc/15709
For multicentric castleman disease medicines or chemotherapy is used to shrink the tumor. Mostly drugs are used in combination for the treatment. Radiotherapy can also be used to destroy affected tissues. Castleman disease treatment market especially antiviral treatment is expected to show growth as cases of HIV-associated castleman disease are increasing and If not treated properly this condition can be life-threatening. Monoclonal antibodies market is expected to be fastest growing segment due to its targeted effect.
Increasing awareness among physicians regarding this disease is projected to drive this growth. The presence of key players and government policies helping the development of drugs for orphan diseases are also the factor for the growth of this market.
Some of the market participants in the global castleman disease treatment market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Co, Merck & Co. Inc., Pfizer Inc., Hospira Inc., Incyte Corp., and Novartis AG. Currently only Siltuximab by Johnson & Johnson has been approved by FDA specifically for multicentric castleman disease.
There is vast opportunity available for companies in this market. Government support for orphan drug development will encourage the companies to develop drugs for castleman disease. Companies are focusing on research & development and performing clinical trials on already existing anticancer drugs to get approval for their effect against multicentric castleman disease.
About Us :-
Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.
Contact us:
Persistence Market Research
Address – 305 Broadway, 7th FloorNew York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com